WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
26 August 2012
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
15 August 2012
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
16 July 2012
GSK and Theravance announce regulatory submissions for FF/VI
15 July 2012
Innovative public-private collaboration launches to tackle antibiotic research
24 May 2012
GlaxoSmithKline to fully acquire Cellzome for £61 million
15 May 2012
GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
11 May 2012
GlaxoSmithKline and Yale University establish drug discovery collaboration
03 May 2012
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
20 April 2012
GSK provides update on corporate responsibility commitments in 2011 report
19 April 2012
Start
Prev
3
4
5
6
7
8
9
10
11
12
Next
End
Business & Industry
Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
Amgen successfully completes acquisition of Five Prime Therapeutics
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Research & Development
Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
Patients who are obese or overweight are at risk for a more severe course of COVID-19
New COVID-19 vaccine may offer broad protection from coronaviruses
SARS-CoV-2: New findings on the persistence of neutralizing antibodies
Massive fragment screen points way to new SARS-CoV-2 inhibitors
B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
COVID-19 causes 'unexpected' cellular response in the lungs
Conferences & Events
Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
CPhI Worldwide to return in 2021
Reuters Events' Cell & Gene Therapy USA
Total health: Build a better healthcare system
Don't fall for the 'next best action' trap
Locking down shape-shifting spike protein aids development of COVID-19 vaccine
COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
You are here:
Home
GlaxoSmithKline
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19